Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jingao Li
Observed names:
J. Li,
JinGao Li,
Li, Jin-Gao,
Li, Jingao
Institutions:
Jiangxi Provincial Cancer Hospital,
Nanchang Medical College
Observed institutions:
Nanchang University,
Chinese Academy of Medical Sciences & Peking Union Medical College,
Jiangxi Provincial Cancer Hospital,
Cancer Hospital of Chinese Academy of Medical Sciences,
Nanchang Medical College
ORCID:
0000-0002-0389-7576
Observed ORCID:
0000-0002-0389-7576
OpenAlex ID:
A5017632172
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial
2026
·
Yan Huang
, Dongchen Sun
, et al.
·
JAMA Oncology
·
17
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study
2026
·
Lisa Licitra
, Makoto Tahara
, et al.
·
Journal of Clinical Oncology
·
13
An open-label, first-in-human study of SKB500 in patients with locally advanced or metastatic solid tumors.
2026
·
Xueying Zhang
, Wen Gao
, et al.
·
Journal of Clinical Oncology
·
2
847O Sequential chemoradiotherapy versus induction chemotherapy plus concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: A multicentre, open-label, non-inferiority, randomised, phase III trial
2024
·
C. Hu
, F. Xue
, et al.
·
Annals of Oncology
·
1
P84.17 Impacts of Different EML4-ALK Variants on the Efficacy of ALK Inhibitors in ALK Positive NSCLC——A Real-World Study in China.
2021
·
Z. Zou
, Y. Li
, et al.
·
Journal of Thoracic Oncology
·
1
A two-stage genome-wide association study to identify germline polymorphisms associated with survival of nasopharyngeal carcinoma
2026
·
Tong Li
, LuLu Yu
, et al.
·
Pathology - Research and Practice
Supplementary Data1 from Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial
2026
·
Dongchen Sun
, Gang Chen
, et al.
Data from Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial
2026
·
Dongchen Sun
, Gang Chen
, et al.
Protocol1 from Anti–LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial
2026
·
Dongchen Sun
, Gang Chen
, et al.
Show more works
View as search
Works count:
14
Citation count:
34
H-index:
2
I10-index:
2
Year
Topic
Type